ArticleCureus2025
Dexmedetomidine for Alcohol Withdrawal: Looks Can Be Deceiving.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol is a gamma-aminobutyric acid (GABA) receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist. Although benzodiazepines and barbiturates are the standard treatments for alcohol withdrawal, there is some recent interest in adding dexmedetomidine. We report cases of two patients with severe alcohol withdrawal to highlight some limitations of dexmedetomidine therapy. The first case was of a 58-year-old man who presented with severe alcohol withdrawal. He received chlordiazepoxide, diazepam, and phenobarbital with resolution of his symptoms. He was later started on dexmedetomidine (0.2 mcg/kg/hr), with no other therapy, during which time he appeared sedated with a heart rate (HR) of 80 beats/minute, blood pressure (BP) of 126/80 mmHg, and respiratory rate (RR) of 18 breaths/minute. Seven hours after stopping the infusion, he said that he "had been lying in bed staring at the ceiling feeling like hell… felt extremely agitated in my head". The second patient was a 41-year-old man who developed alcohol withdrawal and required intubation seven hours after presentation. Maximal sedation was 50 mcg/kg/min of propofol and 14 mg/hr of midazolam. On hospital day 3, the team stopped propofol, decreased midazolam to 10 mg/hour, and added dexmedetomidine 0.2 mg/kg/hr. Forty minutes later, the toxicology team observed the patient unresponsive with left gaze deviation and rhythmic eye movements. Video EEG was consistent with a seizure. The patient's EEG rapidly improved with a midazolam bolus. Although dexmedetomidine controls the autonomic instability and behavior associated with alcohol withdrawal, it does not address the underlying pathophysiology, leaving patients to suffer the psychological effects of withdrawal. The role of dexmedetomidine remains to be determined, with studies that address cognitive and long-term outcomes of alcohol withdrawal rather than just vital signs, behavior, and doses of other medications used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.